Funder: Amsterdam UMC, AG&M institute talent development grantAbstract: Survival rates of cancer patients vary widely within and between malignancies. While genetic aberrations are at the root of all cancers, individual genomic features cannot explain these distinct disease outcomes. In contrast, intra-tumour heterogeneity (ITH) has the potential to elucidate pan-cancer survival rates and the biology that drives cancer prognosis. Unfortunately, a comprehensive and effective framework to measure ITH across cancers is missing. Here, we introduce a scalable measure of chromosomal copy number heterogeneity (CNH) that predicts patient survival across cancers. We show that the level of ITH can be derived from a single-sample copy number profile. ...
Genetic heterogeneity between and within tumours is a major factor determining cancer progression an...
Cancer is a complex disease and presents one of the greatest challenges in modern medicine. Despite ...
Intra-tumor heterogeneity (ITH) is a mechanism of therapeutic resistance and therefore an important ...
Survival rates of cancer patients vary widely within and between malignancies. While genetic aberrat...
Survival rates of cancer patients vary widely within and between malignancies. While genetic aberrat...
Intratumor heterogeneity (ITH) drives neoplastic progression and therapeutic resistance. We used the...
Intratumor heterogeneity (ITH) drives neoplastic progression and therapeutic resistance. We used the...
Mutant allele frequency distributions in cancer samples have been used to estimate intratumoral hete...
Tumours do not consist of a single homogeneous population but are complex heterogeneous systems that...
Intra-tumour genetic heterogeneity (ITH) fosters drug resistance and is a critical hurdle to clinica...
Intra-tumor heterogeneity (ITH) is a mechanism of therapeutic resistance and therefore an important ...
<div><p>Chromosomal instability is a well-defined hallmark of tumor aggressiveness and metastatic pr...
Genomic aberrations such as copy number alterations (CNA) and loss of heterozygosity (LOH) are hallm...
Genetic heterogeneity between and within tumours is a major factor determining cancer progression an...
We developed subclone multiplicity allocation and somatic heterogeneity (SMASH), a new statistical m...
Genetic heterogeneity between and within tumours is a major factor determining cancer progression an...
Cancer is a complex disease and presents one of the greatest challenges in modern medicine. Despite ...
Intra-tumor heterogeneity (ITH) is a mechanism of therapeutic resistance and therefore an important ...
Survival rates of cancer patients vary widely within and between malignancies. While genetic aberrat...
Survival rates of cancer patients vary widely within and between malignancies. While genetic aberrat...
Intratumor heterogeneity (ITH) drives neoplastic progression and therapeutic resistance. We used the...
Intratumor heterogeneity (ITH) drives neoplastic progression and therapeutic resistance. We used the...
Mutant allele frequency distributions in cancer samples have been used to estimate intratumoral hete...
Tumours do not consist of a single homogeneous population but are complex heterogeneous systems that...
Intra-tumour genetic heterogeneity (ITH) fosters drug resistance and is a critical hurdle to clinica...
Intra-tumor heterogeneity (ITH) is a mechanism of therapeutic resistance and therefore an important ...
<div><p>Chromosomal instability is a well-defined hallmark of tumor aggressiveness and metastatic pr...
Genomic aberrations such as copy number alterations (CNA) and loss of heterozygosity (LOH) are hallm...
Genetic heterogeneity between and within tumours is a major factor determining cancer progression an...
We developed subclone multiplicity allocation and somatic heterogeneity (SMASH), a new statistical m...
Genetic heterogeneity between and within tumours is a major factor determining cancer progression an...
Cancer is a complex disease and presents one of the greatest challenges in modern medicine. Despite ...
Intra-tumor heterogeneity (ITH) is a mechanism of therapeutic resistance and therefore an important ...